Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc. has reported a significant increase in net product revenues, with a 140% rise to $607.6k for FY24 and a notable 223% year-over-year increase in Q3 FY25 net product revenue. The company’s ARAKODA product is demonstrating strong sales growth, evidenced by a 14% increase in deliveries during Q3 FY25, suggesting a solid market demand and potential for further expansion. Additionally, the favorable safety profile of tafenoquine presents opportunities for innovative combination therapies, enhancing the firm's potential commercialization avenues amidst a growing market for infectious disease treatments.

Bears say

60 Degrees Pharmaceuticals Inc is facing a challenging outlook primarily due to a lack of visibility regarding revenue growth, evidenced by a sequential decline in product revenues to $100,000 amid supply constraints. The reported gross loss of approximately $9,000, a stark contrast to the gross profit of $36,000 in Q3 FY24, stems from a one-time inventory write-off, further highlighting the company's financial vulnerabilities. Additionally, low visibility on regulatory approvals for new therapies and potential dilution from financing pose significant risks that could impede the company's financial performance and stock valuation.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.